CORRELATION BETWEEN THE ATMOSPHERIC ELECTRIC FIELD MEASURED ON THE PACIFIC AND ATLANTIC OCEANS AND ANTARCTICA

1971-03-30The atmospheric electric field measured on the research vessel, "Hakuho-Maru", on the Mid- and South-Pacific Ocean was compared with that measured at Syowa Station in Antarctica and on two vessels on the Mid-Atlantic ocean. The ratio of daily averages on Hakuho-Maru and at Syowa Station alters in accordance with the advance of Hakuho-Maru, and it suggests the latitude effect characterized by the gradual decrease toward the antarctic region. The correlation of the diurnal course of the electric field among these globally representative stations is much higher than that among the land stations. This indicates the influence of the atmospheric electrical generator extends over the entire globe without significant attenuation.departmental bulletin pape

西淀川公害訴訟における共同不法行為論 : 公害法理論形成における「理論と実務の協働（澤井裕教授の事蹟を中心に）

departmental bulletin pape

福島原発事故賠償訴訟における「損害論」の動向（1) : 仙台・東京高裁判決の検討を中心に

departmental bulletin pape

強制不妊手術国賠訴訟における「時の壁」 : 民法解釈方法論からの考察

departmental bulletin pape

障害児死亡における損害賠償額の算定について

departmental bulletin pape

建設アスベスト訴訟最高裁判決（最判令3・5・17民集75巻5号1359頁、同6号2303頁、判時2498号52頁、同2500号49頁）の検討 ： 建材メーカーの責任を中心に

departmental bulletin pape

福島原発事故における被侵害権利・法益 : 「滞在者」の被害を中心に

departmental bulletin pape

Close correlation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N(4)-behenoyl-1-beta-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia.

N(4)-Behenoyl-1-beta-D-arabinofuranosylcytosine (BHAC), a prodrug of 1-beta-D-arabinofuranosylcytosine, is used effectively for the treatment of leukemia in Japan. BHAC therapy may be more effective if it is delivered in conjunction with monitoring of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate (ara-CTP), the intracellular active metabolite of ara-C derived from BHAC. However, previous monitoring methods for ara-CTP were insufficiently sensitive. Here, using our new sensitive method, we evaluated the ara-CTP pharmacokinetics in relation to the therapeutic response in 11 acute myelogenous leukemia patients who received a 2-h infusion of BHAC (70 mg / m(2)) in combination remission induction therapy. ara-CTP could be monitored at levels under 1 mM. BHAC maintained effective levels of plasma ara-C and intracellular ara-CTP for a longer time, even compared with historical values of high-dose ara-C. The area under the concentration-time curve of ara-CTP was significantly greater in the patients with complete remission than in the patients without response. This greater amount of ara-CTP was attributed to the higher ara-CTP concentrations achieved in the responding patients. There was no apparent difference of plasma ara-C pharmacokinetics between the two groups. Thus, for the first time, the ara-CTP pharmacokinetics was evaluated in relation to the therapeutic effect of BHAC, and the importance of ara-CTP was proven. Administration of optimal BHAC therapy may require monitoring of the ara-CTP pharmacokinetics in each individual patient.othe

The Effect of Surface Treatment of Ti-6Al-4V Alloy Specimens

論文(Article)journal articl